Klaus Diergarten, MD

Articles by Klaus Diergarten, MD

Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic

ByUte Klaassen, MD,Hans Jochen Wilke, MD,Christian Müller, MD,David Borquez, MD,Michael Korn, MD,Klaus Diergarten, MD,Siegfried Seeber, MD, PhD

April 1st 1997

Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil(5-FU)/folinic acid (HD5-FU/FA) in intensively pretreated patients with metastatic

Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer

ByHans-Joachim Lück, MD,Andreas Du Bois, MD, PhD,Christoph Thomssen, MD, PhD,Björn Lisboa, MD, PhD,Michael Untch, MD, PhD,Günther Köhler, MD, PhD,Detlev Hecker, PhD,Klaus Diergarten, MD

April 1st 1997

Paclitaxel (Taxol) has aroused considerable interest for its high single-agent activity in breast cancer and novel mechanism of action. Epirubicin (Farmorubicin), the 4'epimer of doxorubicin (Adriamycin), also has high activity in

Latest Updated Articles

Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic
Published: April 1st 1997 | Updated:
Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer
Published: April 1st 1997 | Updated:

Klaus Diergarten, MD

Articles by Klaus Diergarten, MD

Infusional 5-FU, Folinic Acid, Paclitaxel, and Cisplatin for Metastatic

Paclitaxel and Epirubicin as First-Line Therapy for Patients With Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

FDA Issues CRL for Dasatinib in CML/ALL

Why is Radiotherapy Not More Accessible as a Cancer Treatment?

Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer

Patient With RRMM, Cytopenias, COPD, and Progressive Bone Disease

FDA Accepts Resubmission of BLA for RP1/Nivolumab in Advanced Melanoma